Eicosapentaenoic acid reduces membrane fluidity, inhibits cholesterol domain formation, and normalizes bilayer width in atherosclerotic-like model membranes

Biochimica et Biophysica Acta - Biomembranes

Volumn 1858, Issue 12, 2016, Pages 3131-3140

  Mason, R Preston ^a,b   Jacob, Robert F ^b   Shrivastava, Sandeep ^c   Sherratt, Samuel C R ^b   Chattopadhyay, Amitabha ^c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b ELUCIDA RESEARCH LLC   (United States)

^c CENTRE FOR CELLULAR AND MOLECULAR BIOLOGY   (India)

Author keywords

Cholesterol domain; Docosahexaenoic acid (DHA); Eicosapentaenoic acid (EPA); Membrane fluidity; Membrane structure

Indexed keywords

ARACHIDONIC ACID; CHOLESTEROL; DOCOSAHEXAENOIC ACID; FENOFIBRATE; GEMFIBROZIL; GLYCYRRHIZIC ACID; ICOSAPENTAENOIC ACID; LINOLENIC ACID; NICOTINIC ACID; PHOSPHOLIPID; LIPID BILAYER;

ARTICLE; ATHEROSCLEROSIS; BILAYER MEMBRANE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CRYSTAL STRUCTURE; DRUG MECHANISM; LIPID MEMBRANE; MEMBRANE FLUIDITY; MEMBRANE STRUCTURE; PRIORITY JOURNAL; TEMPERATURE; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; HUMAN; LIPID BILAYER;

ATHEROSCLEROSIS; CHOLESTEROL; DOCOSAHEXAENOIC ACIDS; DOSE-RESPONSE RELATIONSHIP, DRUG; EICOSAPENTAENOIC ACID; HUMANS; LIPID BILAYERS; MEMBRANE FLUIDITY;

EID: 84991463667     PISSN: 00052736     EISSN: 18792642     Source Type: Journal    
DOI: 10.1016/j.bbamem.2016.10.002     Document Type: Article

References (74)

1. [1] Libby, P., Inflammation in atherosclerosis. Nature 420 (2002), 868–874.
2. [2] Kellner-Weibel, G., Yancey, P.G., Jerome, W.G., Walser, T., Mason, R.P., Phillips, M.C., Rothblat, G.H., Crystallization of free cholesterol in model macrophage foam cells. Arterioscler. Thromb. Vasc. Biol. 19 (1999), 1891–1898.
3. [3] Tulenko, T.N., Chen, M., Mason, P.E., Mason, R.P., Physical effects of cholesterol on arterial smooth muscle membranes: evidence of immiscible cholesterol domains and alterations in bilayer width during atherogenesis. J. Lipid Res. 39 (1998), 947–956.
4. [4] Borow, K.M., Nelson, J.R., Mason, R.P., Biologic plausibility, cellular effects, and molecular mechanisms of eicosapentaenoic acid (EPA) in atherosclerosis. Atherosclerosis 242 (2015), 357–366.
5. [5] Mason, R.P., Jacob, R.F., Membrane microdomains and vascular biology: emerging role in atherogenesis. Circulation 107 (2003), 2270–2273.
6. [6] Abela, G.S., Aziz, K., Cholesterol crystals rupture biological membranes and human plaques during acute cardiovascular events—a novel insight into plaque rupture by scanning electron microscopy. Scanning 28 (2006), 1–10.
7. [7] Phillips, J.E., Geng, Y.J., Mason, R.P., 7-Ketocholesterol forms crystalline domains in model membranes and murine aortic smooth muscle cells. Atherosclerosis 159 (2001), 125–135.
8. [8] Small, D.M., Progression and regression of atherosclerotic lesions. Insights from lipid physical biochemistry. Arterioscler. Thromb. Vasc. Biol. 8 (1988), 103–129.
9. [9] Cohen, A.W., Combs, T.P., Scherer, P.E., Lisanti, M.P., Role of caveolin and caveolae in insulin signaling and diabetes. Am. J. Physiol. Endocrinol. Metab. 285 (2003), E1151–E1160.
10. [10] Bertelsen, M., Anggard, E.E., Carrier, M.J., Oxidative stress impairs insulin internalization in endothelial cells in vitro. Diabetologia 44 (2001), 605–613.
11. [11] Fruchart, J.C., Davignon, J., Hermans, M.P., Al-Rubeaan, K., Amarenco, P., Assmann, G., Barter, P., Betteridge, J., Bruckert, E., Cuevas, A., Farnier, M., Ferrannini, E., Fioretto, P., Genest, J., Ginsberg, H.N., Gotto, A.M., Jr., D.H., Kadowaki, T., Kodama, T., Krempf, M., Matsuzawa, Y., Nunez-Cortes, J.M., Monfil, C.C., Ogawa, H., Plutzky, J., Rader, D.J., Sadikot, S., Santos, R.D., Shlyakhto, E., Sritara, P., Sy, R., Tall, A., Tan, C.E., Tokgozoglu, L., Toth, P.P., Valensi, P., Wanner, C., Zambon, A., Zhu, J., Zimmet, P., I. residual risk reduction, residual macrovascular risk in 2013: what have we learned?. Cardiovasc. Diabetol., 13, 2014, 26.
12. [12] Varbo, A., Benn, M., Nordestgaard, B.G., Remnant cholesterol as a cause of ischemic heart disease: evidence, definition, measurement, atherogenicity, high risk patients, and present and future treatment. Pharmacol. Ther. 141 (2014), 358–367.
13. [13] Varbo, A., Benn, M., Tybjaerg-Hansen, A., Jorgensen, A.B., Frikke-Schmidt, R., Nordestgaard, B.G., Remnant cholesterol as a causal risk factor for ischemic heart disease. J. Am. Coll. Cardiol. 61 (2013), 427–436.
14. [14] Varbo, A., Benn, M., Tybjaerg-Hansen, A., Nordestgaard, B.G., Elevated remnant cholesterol causes both low-grade inflammation and ischemic heart disease, whereas elevated low-density lipoprotein cholesterol causes ischemic heart disease without inflammation. Circulation 128 (2013), 1298–1309.
15. [15] Liu, J., Zeng, F.F., Liu, Z.M., Zhang, C.X., Ling, W.H., Chen, Y.M., Effects of blood triglycerides on cardiovascular and all-cause mortality: a systematic review and meta-analysis of 61 prospective studies. Lipids Health Dis., 12, 2013, 159.
16. [16] Zheng, C., Khoo, C., Ikewaki, K., Sacks, F.M., Rapid turnover of apolipoprotein C-III-containing triglyceride-rich lipoproteins contributing to the formation of LDL subfractions. J. Lipid Res. 48 (2007), 1190–1203.
17. [17] GISSI-Prevenzione Investigators, Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Lancet 354 (1999), 447–455.
18. [18] Matsuzaki, M., Yokoyama, M., Saito, Y., Origasa, H., Ishikawa, Y., Oikawa, S., Sasaki, J., Hishida, H., Itakura, H., Kita, T., Kitabatake, A., Nakaya, N., Sakata, T., Shimada, K., Shirato, K., Matsuzawa, Y., Investigators, J., Incremental effects of eicosapentaenoic acid on cardiovascular events in statin-treated patients with coronary artery disease. Circ. J. 73 (2009), 1283–1290.
19. [19] Yokoyama, M., Origasa, H., Matsuzaki, M., Matsuzawa, Y., Saito, Y., Ishikawa, Y., Oikawa, S., Sasaki, J., Hishida, H., Itakura, H., Kita, T., Kitabatake, A., Nakaya, N., Sakata, T., Shimada, K., Shirato, K., Japan, E.P.A.l.i.s.I., Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis. Lancet 369 (2007), 1090–1098.
20. [20] Saito, Y., Yokoyama, M., Origasa, H., Matsuzaki, M., Matsuzawa, Y., Ishikawa, Y., Oikawa, S., Sasaki, J., Hishida, H., Itakura, H., Kita, T., Kitabatake, A., Nakaya, N., Sakata, T., Shimada, K., Shirato, K., Jelis Investigators, J., Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: sub-analysis of primary prevention cases from the Japan EPA Lipid Intervention Study (JELIS). Atherosclerosis 200 (2008), 135–140.
21. [21] Tanaka, K., Ishikawa, Y., Yokoyama, M., Origasa, H., Matsuzaki, M., Saito, Y., Matsuzawa, Y., Sasaki, J., Oikawa, S., Hishida, H., Itakura, H., Kita, T., Kitabatake, A., Nakaya, N., Sakata, T., Shimada, K., Shirato, K., Jelis Investigators, J., Reduction in the recurrence of stroke by eicosapentaenoic acid for hypercholesterolemic patients: subanalysis of the JELIS trial. Stroke 39 (2008), 2052–2058.
22. [22] Casula, M., Soranna, D., Catapano, A.L., Corrao, G., Long-term effect of high dose omega-3 fatty acid supplementation for secondary prevention of cardiovascular outcomes: a meta-analysis of randomized, placebo controlled trials [corrected]. Atheroscler. Suppl. 14 (2013), 243–251.
23. [23] Risk Prevention Study Collaborative Group, Roncaglioni, M.C., Tombesi, M., Avanzini, F., Barlera, S., Caimi, V., Longoni, P., Marzona, I., Milani, V., Silletta, M.G., Tognoni, G., Marchioli, R., n-3 fatty acids in patients with multiple cardiovascular risk factors. N. Engl. J. Med. 368 (2013), 1800–1808.
24. [24] Rizos, E.C., Ntzani, E.E., Bika, E., Kostapanos, M.S., Elisaf, M.S., Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-analysis. JAMA 308 (2012), 1024–1033.
25. [25] Rauch, B., Schiele, R., Schneider, S., Diller, F., Victor, N., Gohlke, H., Gottwik, M., Steinbeck, G., Del Castillo, U., Sack, R., Worth, H., Katus, H., Spitzer, W., Sabin, G., Senges, J., Group, O.S., OMEGA, a randomized, placebo-controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline-adjusted therapy after myocardial infarction. Circulation 122 (2010), 2152–2159.
26. [26] Origin Trial Investigators, Bosch, J., Gerstein, H.C., Dagenais, G.R., Diaz, R., Dyal, L., Jung, H., Maggiono, A.P., Probstfield, J., Ramachandran, A., Riddle, M.C., Ryden, L.E., Yusuf, S., n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. N. Engl. J. Med. 367 (2012), 309–318.
27. [27] Galan, P., Kesse-Guyot, E., Czernichow, S., Briancon, S., Blacher, J., Hercberg, S., Group, S.F.O.C., Effects of B vitamins and omega 3 fatty acids on cardiovascular diseases: a randomised placebo controlled trial. Br. Med. J., 341, 2010, c6273.
28. [28] GISSI Heart Failure Investigators, Tavazzi, L., Maggioni, A.P., Marchioli, R., Barlera, S., Franzosi, M.G., Latini, R., Lucci, D., Nicolosi, G.L., Porcu, M., Tognoni, G., Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial. Lancet 372 (2008), 1223–1230.
29. [29] Kromhout, D., Giltay, E.J., Geleijnse, J.M., G. Alpha Omega Trial, n-3 fatty acids and cardiovascular events after myocardial infarction. N. Engl. J. Med. 363 (2010), 2015–2026.
30. [30] Marchioli, R., Barzi, F., Bomba, E., Chieffo, C., Di Gregorio, D., Di Mascio, R., Franzosi, M.G., Geraci, E., Levantesi, G., Maggioni, A.P., Mantini, L., Marfisi, R.M., Mastrogiuseppe, G., Mininni, N., Nicolosi, G.L., Santini, M., Schweiger, C., Tavazzi, L., Tognoni, G., Tucci, C., Valagussa, F., G.I.-P. Investigators, Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-Prevenzione. Circulation 105 (2002), 1897–1903.
31. [31] Shaikh, S.R., Biophysical and biochemical mechanisms by which dietary N-3 polyunsaturated fatty acids from fish oil disrupt membrane lipid rafts. J. Nutr. Biochem. 23 (2012), 101–105.
32. [32] Shaikh, S.R., Kinnun, J.J., Leng, X., Williams, J.A., Wassall, S.R., How polyunsaturated fatty acids modify molecular organization in membranes: insight from NMR studies of model systems. Biochim. Biophys. Acta 1848 (2015), 211–219.
33. [33] Williams, J.A., Batten, S.E., Harris, M., Rockett, B.D., Shaikh, S.R., Stillwell, W., Wassall, S.R., Docosahexaenoic and eicosapentaenoic acids segregate differently between raft and nonraft domains. Biophys. J. 103 (2012), 228–237.
34. [34] Bays, H.E., Ballantyne, C.M., Braeckman, R.A., Stirtan, W.G., Soni, P.N., Icosapent ethyl, a pure ethyl ester of eicosapentaenoic acid: effects on circulating markers of inflammation from the MARINE and ANCHOR studies. Am. J. Cardiovasc. Drugs 13 (2013), 37–46.
35. [35] Wakita, Y., Wakita, Y., Itou, T., Mizuno, R., High purity eicosapentaenoic acid in addition to a strong statin makes regression of intima-media thickness in patients with asymptomatic cerebral infarction [Abstract 413]. Stroke, 44, 2013, WP413.
36. [36] Uehara, H., Miyagi, N., Shimajiri, M., Nago, C., The additional effect of eicosapentaenoic acid on coronary plaque stability in stable angina patients with statin use by optical coherence tomography analysis [abstract P5495]. Eur. Heart J., 34(Suppl. 1), 2013, 1011.
37. [37] Nishio, R., Shinke, T., Otake, H., Nakagawa, M., Nagoshi, R., Inoue, T., Kozuki, A., Hariki, H., Osue, T., Taniguchi, Y., Iwasaki, M., Hiranuma, N., Konishi, A., Kinutani, H., Shite, J., Hirata, K., Stabilizing effect of combined eicosapentaenoic acid and statin therapy on coronary thin-cap fibroatheroma. Atherosclerosis 234 (2014), 114–119.
38. [38] Niki, T., Wakatsuki, T., Bando, M., Ogasawara, K., Bando, S., Matsuura, T., Hotch, J., Yamaguchi, K., Taketani, Y., Iwase, T., Iwase, T., Tomita, N., Yamada, H., Soeki, T., Sata, M., Effects of additional eicosapentaenoic adic to statin therapy on inflammatory cytokines and the tissue characterization of coronary plaque assessed by integrated backscatter intravascular ultrasound systems [abstract 14434]. Circulation, 126, 2012, 14434.
39. [39] Ando, K., Watanabe, T., Daidoji, H., Otaki, Y., Hashimoto, N., Kumagai, Y., Hashimoto, N., Narumi, T., Kadowaki, S., Yamaura, G., Wanezaki, M., Funayama, A., Yashiro, Y., Iwayama, T., Nishiyama, S., Takahashi, H., Arimoto, T., Shishido, T., Miyamoto, T., Kubota, I., Combination therapy of eicosapentaenoic acid and pitavastatin for coronary plaque regression evaluated by integrated backscatter intravascular ultrasonography: a randomized controlled trial [abstract A12007]. Circulation, 132, 2015, A12007.
40. [40] Domei, T., Amemiya, K., Enomoto, S., Ichihashi, K., Yokoi, M., Iwabuchi, M., Nobuyoshi, M., Eicosapentaenoic acid reduced the progression of the coronary atherosclerosis in the patients with optimal LDL cholesterol lowering therapy [abstract P689]. Eur. Heart J., 34(Suppl. 1), 2013, 137.
41. [41] Shintani, Y., Kawasaki, T., The impact of a pure-EPA omega-3 fatty acid on coronary plaque stabilization: a plaque component analysis with 64-slice multi-detector row computed tomography [abstract 1181-152]. Presented at the 61st Annual Scientific Session and Expo at the American College of Cardiology, March 2012.
42. [42] Yamano, T., Kubo, T., Shiono, Y., Shimamura, K., Orii, M., Tanimoto, T., Matsuo, Y., Ino, Y., Kitabata, H., Yamaguchi, T., Hirata, K., Tanaka, A., Imanishi, T., Akasaka, T., Impact of eicosapentaenoic acid treatment on the fibrous cap thickness in patients with coronary atherosclerotic plaque: an optical coherence tomography study. J. Atheroscler. Thromb. 22 (2015), 52–61.
43. [43] Kim, W., Barhoumi, R., McMurray, D.N., Chapkin, R.S., Dietary fish oil and DHA down-regulate antigen-activated CD4 + T-cells while promoting the formation of liquid-ordered mesodomains. Br. J. Nutr. 111 (2014), 254–260.
44. [44] Kim, W., Fan, Y.Y., Barhoumi, R., Smith, R., McMurray, D.N., Chapkin, R.S., n-3 polyunsaturated fatty acids suppress the localization and activation of signaling proteins at the immunological synapse in murine CD4 + T cells by affecting lipid raft formation. J. Immunol. 181 (2008), 6236–6243.
45. [45] Sasaki, J., Miwa, T., Odawara, M., Administration of highly purified eicosapentaenoic acid to statin-treated diabetic patients further improves vascular function. Endocr. J. 59 (2012), 297–304.
46. [46] Guichardant, M., Calzada, C., Bernoud-Hubac, N., Lagarde, M., Vericel, E., Omega-3 polyunsaturated fatty acids and oxygenated metabolism in atherothrombosis. Biochim. Biophys. Acta 1851 (2015), 485–495.
47. [47] Mason, R.P., Jacob, R.F., Eicosapentaenoic acid inhibits glucose-induced membrane cholesterol crystalline domain formation through a potent antioxidant mechanism. Biochim. Biophys. Acta 1848 (2015), 502–509.
48. [48] Mason, R.P., Sherratt, S.C., Jacob, R.F., Eicosapentaenoic acid inhibits oxidation of ApoB-containing lipoprotein particles of different size in vitro when administered alone or in combination with atorvastatin active metabolite compared with other triglyceride-lowering agents. J. Cardiovasc. Pharmacol. 68 (2016), 33–40.
49. [49] Sakamoto, S., Nakahara, H., Uto, T., Shoyama, Y., Shibata, O., Investigation of interfacial behavior of glycyrrhizin with a lipid raft model via a Langmuir monolayer study. Biochim. Biophys. Acta 1828 (2013), 1271–1283.
50. [50] Jacob, R.F., Mason, R.P., Lipid peroxidation induces cholesterol domain formation in model membranes. J. Biol. Chem. 280 (2005), 39380–39387.
51. [51] Ruocco, M.J., Shipley, G.G., Interaction of cholesterol with galactocerebroside and galactocerebroside-phosphatidylcholine bilayer membranes. Biophys. J. 46 (1984), 695–707.
52. [52] Bangham, A.D., Standish, M.M., Watkins, J.C., Diffusion of univalent ions across the lamellae of swollen phospholipids. J. Mol. Biol. 13 (1965), 238–252.
53. [53] Herbette, L., DeFoor, P., Fleischer, S., Pascolini, D., Scarpa, A., Blasie, J.K., The separate profile structures of the functional calcium pump protein and the phospholipid bilayer within isolated sarcoplasmic reticulum membranes determined by X-ray and neutron diffraction. Biochim. Biophys. Acta 817 (1985), 103–122.
54. [54] Mason, R.P., Gonye, G.E., Chester, D.W., Herbette, L.G., Partitioning and location of Bay K 8644, 1,4-dihydropyridine calcium channel agonist, in model and biological membranes. Biophys. J. 55 (1989), 769–778.
55. [55] Mason, R.P., Walter, M.F., Day, C.A., Jacob, R.F., Active metabolite of atorvastatin inhibits membrane cholesterol domain formation by an antioxidant mechanism. J. Biol. Chem. 281 (2006), 9337–9345.
56. [56] Garg, S., Castro-Roman, F., Porcar, L., Butler, P., Bautista, P.J., Krzyzanowski, N., Perez-Salas, U., Cholesterol solubility limit in lipid membranes probed by small angle neutron scattering and MD simulations. Soft Matter 10 (2014), 9313–9317.
57. [57] Huang, J., Buboltz, J.T., Feigenson, G.W., Maximum solubility of cholesterol in phosphatidylcholine and phosphatidylethanolamine bilayers. Biochim. Biophys. Acta 1417 (1999), 89–100.
58. [58] Shrivastava, S., Paila, Y.D., Dutta, A., Chattopadhyay, A., Differential effects of cholesterol and its immediate biosynthetic precursors on membrane organization. Biochemistry 47 (2008), 5668–5677.
59. [59] Epand, R.M., Bach, D., Wachtel, E., In vitro determination of the solubility limit of cholesterol in phospholipid bilayers. Chem. Phys. Lipids 199 (2016), 3–10.
60. [60] Bach, D., Wachtel, E., Phospholipid/cholesterol model membranes: formation of cholesterol crystallites. Biochim. Biophys. Acta 1610 (2003), 187–197.
61. [61] Barrett, M.A., Zheng, S., Toppozini, L.A., Alsop, R.J., Dies, H., Wang, A., Jago, N., Moore, M., Rheinstädter, M.C., Solubility of cholesterol in lipid membranes and the formation of immiscible cholesterol plaques at high cholesterol concentrations. Soft Matter, 9, 2013, 9342.
62. [62] Hashimoto, M., Hossain, S., Yamasaki, H., Yazawa, K., Masumura, S., Effects of eicosapentaenoic acid and docosahexaenoic acid on plasma membrane fluidity of aortic endothelial cells. Lipids 34 (1999), 1297–1304.
63. [63] Soubias, O., Gawrisch, K., Docosahexaenoyl chains isomerize on the sub-nanosecond time scale. J. Am. Chem. Soc. 129 (2007), 6678–6679.
64. [64] Wassall, S.R., Stillwell, W., Docosahexaenoic acid domains: the ultimate non-raft membrane domain. Chem. Phys. Lipids 153 (2008), 57–63.
65. [65] Usui, K., Hiraki, T., Kawamoto, J., Kurihara, T., Nogi, Y., Kato, C., Abe, F., Eicosapentaenoic acid plays a role in stabilizing dynamic membrane structure in the deep-sea piezophile Shewanella violacea: a study employing high-pressure time-resolved fluorescence anisotropy measurement. Biochim. Biophys. Acta 1818 (2012), 574–583.
66. [66] Lu, L., Okada, N., Nakatani, S., Yoshikawa, K., Eicosapentaenoic acid-induced changes in membrane fluidity and cell adhesion molecules in cultured human keratinocytes. Br. J. Dermatol. 133 (1995), 217–222.
67. [67] Yang, X., Sheng, W., Sun, G.Y., Lee, J.C., Effects of fatty acid unsaturation numbers on membrane fluidity and alpha-secretase-dependent amyloid precursor protein processing. Neurochem. Int. 58 (2011), 321–329.
68. [68] Wu, Y., Zhang, C., Dong, Y., Wang, S., Song, P., Viollet, B., Zou, M.H., Activation of the AMP-activated protein kinase by eicosapentaenoic acid (EPA, 20:5 n-3) improves endothelial function in vivo. PLoS One, 7, 2012, e35508.
69. [69] Yan, Y., Jiang, W., Spinetti, T., Tardivel, A., Castillo, R., Bourquin, C., Guarda, G., Tian, Z., Tschopp, J., Zhou, R., Omega-3 fatty acids prevent inflammation and metabolic disorder through inhibition of NLRP3 inflammasome activation. Immunity 38 (2013), 1154–1163.
70. [70] Martinez, G.J., Robertson, S., Barraclough, J., Xia, Q., Mallat, Z., Bursill, C., Celermajer, D.S., Patel, S., Colchicine acutely suppresses local cardiac production of inflammatory cytokines in patients with an acute coronary syndrome. J. Am. Heart Assoc., 4, 2015, e002128.
71. [71] Nidorf, S.M., Verma, S., Is there a role for colchicine in acute coronary syndromes?. J. Am. Heart Assoc., 4, 2015, e002372.
72. [72] Liu, X., Xue, Y., Liu, C., Lou, Q., Wang, J., Yanagita, T., Xue, C., Wang, Y., Eicosapentaenoic acid-enriched phospholipid ameliorates insulin resistance and lipid metabolism in diet-induced-obese mice. Lipids Health Dis., 12, 2013, 109.
73. [73] Geleijnse, J.M., Giltay, E.J., Schouten, E.G., de Goede, J., Oude Griep, L.M., Teitsma-Jansen, A.M., Katan, M.B., Kromhout, D., G. Alpha Omega Trial, Effect of low doses of n-3 fatty acids on cardiovascular diseases in 4,837 post-myocardial infarction patients: design and baseline characteristics of the Alpha Omega Trial. Am. Heart J. 159 (2010), 539–546, e532.
74. [74] Amarin Pharma Inc., A study of AMR101 to evaluate its ability to reduce cardiovascular events in high risk patients with hypertriglyceridemia and on statin. The primary objective is to evaluate the effect of 4 g/day AMR101 for preventing the occurrence of a first major cardiovascular event (REDUCE-IT). Identifier: NCT01426361. ClinicalTrials.Gov [Internet]. Bethesda, MD: National Library of Medicine (USA). 2015, 2016 March 1 (Available from: https://clinicaltrials.gov/ct2/show/NCT01492361 NLM Identifier NCT01492361).